north40000
11 hours ago
AMRN has traded more in line with the small-cap biotech index, not the XBI or even the Russell 2000 index. I picked AMRN as my top pick in a IHub contest of 10 savvy LT picks that began in early May and will end in late April or May 2025. My entry point for AMRN in the contest is $0.688. Other picks with entry values are CDMO= $7.14, ATNM= $7.40, AVXL= $4.22, MAGS= $45.11, MNMD= $7.21, NVDL= $69.55, NWBO= $0.428, VKTX= $53.01 and XERS= $2.25. None of those picks can be traded on a short term basis; all are LTBuyHOLD. Contestants hope that each of their picks will have a higher share price at contest end next year, with buyouts/M and A activity at multiples of entry values a possibility.
dogn
20 hours ago
Journal of Clinical Lipidology
Volume 18, Issue 4, Supplement, July–August 2024, Page e574
Comparison of Package Insert versus Real World Safety Data from Branded Icosapent Ethyl Users: A Select Analysis Utilizing MarketScan Data.
https://www.sciencedirect.com/science/article/abs/pii/S1933287424001594
Conclusions
RWD demonstrated trends in the frequency of IPE-labeled AEs that are consistent with, but 3-5x lower than, trial and labeling data. Potential reasons for consistently lower AE rates in RWD compared with trial data may be related to differences in how AEs are assessed and documented in the real world vs. in trials.
FlyFishingStocks
23 hours ago
October 25, 2021 Amarin closed at 4.77. Who was running the company? Who was in the Whitehouse? Screwing with the interest rates and giving $Billions to Ukraine? We were neck deep with Covid as well. Perfect storm?
Well, if it has been such a "perfect storm," how do you answer the biotech group index rising from 62.05 to the high today of 102.11 over the past 2 years (a + 65% increase)? AMRN, on the other hand, over that same time frame eroded 64% of its share value; exactly the opposite of its index. That debunks your Whitehouse resident, CEO, Billions to Ukraine, interest rate screw job, and Covid theory.
"Get a life" man.
JRoon71
1 day ago
Kiwi, no disclosure of buyback yet. And no filings. So "officially", no shares purchased yet. But there's still the possibility that Cantor is buying and accumulating in their own account, and have not transferred shares to Amarin yet. I imagine Amarin will need to explain where they are in the process at the CC next week.
As far as shorting, you are correct, board member cannot short. However, this does not prohibit Sarissa (the investment firm) from shorting (as they stated in their proxy) until they reach 10% ownership. It also does not prevent any "partners" from shorting.
But they would not state in their SEC filing that they could potentially short the stock, if that were illegal.
rosemountbomber
1 day ago
Kiwi, not sure if it was because I knew 3 languages before starting kindergarten, but I seemed to have a bit of difficulty with comprehension.
So maybe I am not clear on this, but the SEC rule you posted, I understand to mean that the 10% only applies to shareholders. Otherwise, executives or directors (BOD) would have to declare before shorting the way I comprehend it, right?